---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-24-000107"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:24:11.858144+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GRI Bio Q2 net loss $2.4M; cash runway into Q1 2025; Phase 2a IPF data on track

## Summary
- Net loss of $2.4M for Q2 2024; R&D expense $0.9M; G&A expense $1.4M (down from $5.1M YoY).
- Cash and equivalents $6.4M as of June 30, 2024; public offering in June raised $4.0M gross.
- Cash expected to fund operations into Q1 2025; plans to raise additional funds.
- GRI-0621 Phase 2a IPF biomarker study: interim data Q4 2024, topline data Q1 2025.
- GRI-0803 SLE program progressing preclinically; IND-enabling contingent on funding.

## SEC filing metadata
- accession: 0001824293-24-000107
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000107/0001824293-24-000107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000107/val-20240814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-24-000107
- JSON: https://secwatch.observer/filing/0001824293-24-000107.json
- Plain text: https://secwatch.observer/filing/0001824293-24-000107.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.